leisure time -WSS

leisure time

author：entertainment 2025-09-28 21:06:44 - browse：46927

AI skin cancer detector, dermasensor. -- health tech coverage from STAT — Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but it’s also not that deadly when caught early. Courtesy DermaSensor

The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday, giving primary care physicians a new way to evaluate troubling skin spots.

Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but most types are not that deadly when caught early.

The device, developed by a small company called DermaSensor, is handheld and uses light to examine suspicious moles on a cellular level. It will be marketed specifically for primary care physicians to use in routine check-ups in patients aged 40 and above.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Stanford president faces new allegations over 1999 paper

WSS

Eli Lilly to pay $200M for Beam’s stake in gene

Stanford president faces new allegations over 1999 paper

7 more heat

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Driven by the pandemic, applicants flood public health schools

EF3 tornado rips through North Carolina amid extreme weather nationwide

hotspot

leisure time

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

I learned firsthand about improving diversity in clinical trials

What does generative AI mean for health care? We asked experts

Meta's Zuckerberg and Chan on track to put $50 billion into science

The cancer drug shortage isn’t new — and neither are the solutions

The FDA weighs the risks of candy

BioMarin wins approval for gene therapy to treat hemophilia A

WHO may add ‘noma' to its list of neglected tropical diseases

hotspot

Telehealth options flood the market as retailers push virtual care

Eli Lilly to pay $200M for Beam’s stake in gene

Mass General totes up its waste in a move to tackle climate change

Tocagen's brain cancer gene therapy trial continues. Investors worry

Maker of FluMist seeks to allow at

The pink breast cancer awareness ribbon needs a redesign

knowledge

Wikipedia

hotspot

focus